Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-06
2005-09-06
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S272000, C544S123000, C544S321000
Reexamination Certificate
active
06939872
ABSTRACT:
Compounds of the formula (I): wherein R1, R2, R3, p, q, and X are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
REFERENCES:
patent: 4983608 (1991-01-01), Effland et al.
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5610303 (1997-03-01), Kimura et al.
patent: 5739143 (1998-04-01), Adams et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 2231765 (1998-09-01), None
patent: 0 135 472 (1985-03-01), None
patent: 0 363 002 (1990-04-01), None
patent: 0 379 806 (1990-08-01), None
patent: 0 945 443 (1999-09-01), None
patent: 91/18887 (1991-12-01), None
patent: 92/20642 (1992-11-01), None
patent: 95/09847 (1995-04-01), None
patent: 95/09851 (1995-04-01), None
patent: 95/09852 (1995-04-01), None
patent: 95/09853 (1995-04-01), None
patent: 95/15952 (1995-06-01), None
patent: 96/05177 (1996-02-01), None
patent: 96/28427 (1996-09-01), None
patent: 96/40143 (1996-12-01), None
patent: 97/19065 (1997-05-01), None
patent: 97/35856 (1997-10-01), None
patent: 97/40017 (1997-10-01), None
patent: 97/44326 (1997-11-01), None
patent: 97/47618 (1997-12-01), None
patent: 98/11095 (1998-03-01), None
patent: 98/16230 (1998-04-01), None
patent: 98/18782 (1998-05-01), None
patent: 98/25619 (1998-06-01), None
patent: 98/33798 (1998-08-01), None
patent: 98/41512 (1998-09-01), None
patent: 98/54093 (1998-12-01), None
patent: 98/56788 (1998-12-01), None
patent: 99/01136 (1999-01-01), None
patent: 99/32121 (1999-01-01), None
patent: 99/18096 (1999-04-01), None
patent: 99/18942 (1999-04-01), None
patent: 99/31073 (1999-06-01), None
patent: 99/41253 (1999-08-01), None
patent: 99/50250 (1999-10-01), None
patent: 99/50251 (1999-10-01), None
patent: 00/12485 (2000-03-01), None
patent: 00/12486 (2000-03-01), None
patent: 00/17202 (2000-03-01), None
patent: 00/17203 (2000-03-01), None
patent: 00/21926 (2000-04-01), None
patent: 00/25780 (2000-05-01), None
patent: 00/26209 (2000-05-01), None
patent: 00/39101 (2000-07-01), None
patent: 00/44750 (2000-08-01), None
patent: 00/49018 (2000-08-01), None
patent: 00/53595 (2000-09-01), None
patent: 00/55161 (2000-09-01), None
patent: 00/59892 (2000-10-01), None
patent: 00/78731 (2000-12-01), None
patent: 01/14375 (2001-03-01), None
patent: 01/29009 (2001-04-01), None
patent: 01/30778 (2001-05-01), None
patent: 01/37835 (2001-05-01), None
patent: 01/47897 (2001-07-01), None
patent: 01/47921 (2001-07-01), None
patent: 01/60816 (2001-08-01), None
patent: 01/64653 (2001-09-01), None
patent: 01/64654 (2001-09-01), None
patent: 01/64655 (2001-09-01), None
patent: 01/64656 (2001-09-01), None
patent: 01/72717 (2001-10-01), None
patent: 02/04429 (2002-01-01), None
patent: 02/20512 (2002-03-01), None
patent: 02/066481 (2002-08-01), None
patent: 03/076433 (2003-09-01), None
patent: 03/076434 (2003-09-01), None
patent: 03/076435 (2003-09-01), None
patent: 03/076436 (2003-09-01), None
Volin et al., Cell Cycle Implications in the Pathogenesis of Rheumatoid Arthritis, Frontiers in Bioscience 5, d594-601, Jun. 2000.
Blain et al., Differential Interaction of the Cyclin-dependent Kinase (CDK) Inhibitor p27Kip1 with Cyclin A-CDK2 and Cyclin D2-CDK4, The J. of Biol. Chem., vol. 272, No. 41, pp. 25863-25872, Oct. 1997.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Boschelli et al., Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8-H-pyrido[2,3-d]pyrimidines: Identifidation Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors, J. Med. Chem., vol. 41, 1998, pp. 4365-4377.
Deady et al., “Reactions of some Quinazoline Compounds with Ethoxymethylenemalonic Acid Derivatives”, J. Heterocyclic Chem., vol. 26, 1989, pp. 161-168.
El-Kerdawy et al.; “2,4-Bis (Substituted)-5-Nitropyrimidines of Expected Diuretic Action”; Egypt J. Chem. vol. 29, No. 2, 1986, pp. 247-251.
Fiziol Akt Veshchestva, 1975, vol. 7, pp. 68-72.
Ghosh et al.; “2,4-Bis(arylamino)-5-methylpyrimidines as Antimicrobial Agents”; J. Med. Chem., 1967, vol. 10, No. 5, pp. 974-975.
Ghosh, “2,4-Bis(arylamino)-6-methylpyrimidines as an antimicrobial agents”, Chemical Abstract No. 97712f, vol. 95, 1981, pp. 648.
Schmidt et al.; “A Convenient Synthesis of 2-substituted 4-Amino-5-pyrimidinecarbonitriles”; J. Heterocycle Chem., 1997, vol. 24, No. 5, pp. 1305-1307.
Zimmermann et al., Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC), Arch. Pharm. Pharm. Med. Chem., vol. 329, 1996, pp. 371-376.
Newcombe Nicholas John
Thomas Andrew Peter
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Rao Deepak
LandOfFree
2-anilino-pyrimidine derivatives as cyclin dependent kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-anilino-pyrimidine derivatives as cyclin dependent kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-anilino-pyrimidine derivatives as cyclin dependent kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3402626